Last mentioned: Mar 20, 2026
Data Readout
Expected top-line data from Phase 3 adjunctive MDD trials.
Earnings Call
CEO Sergio Traversa provides update on Reliance II and Reliance III trials.
Enrollment Completion
Anticipated completion of enrollment for the pivotal Reliance II study.
Q4 2025 Close
Relmada concludes fiscal year with focus on Phase 3 enrollment.
Relmada Therapeutics and NeurAxis reported Q4 2025 results, highlighting critical pivots in clinical development and commercial execution. Relmada remains focused on its Phase 3 REL-1017 program for depression, while NeurAxis reports steady growth in its neuromodulation therapy for pediatric patients.
Relmada Therapeutics reported its Q4 2025 results, highlighting progress in its Phase 3 REL-1017 program for major depressive disorder. The company remains focused on completing enrollment for its pivotal trials while maintaining a strategic cash position to reach key clinical milestones.
Relmada Therapeutics and NeurAxis reported Q4 2025 results, highlighting a strategic shift toward late-stage clinical readouts and expanded commercial coverage for CNS therapies. Both companies are positioning themselves as leaders in non-traditional treatments for depression and pediatric pain, respectively.